Mankind Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Mankind Pharma is strategically shifting towards a higher-margin specialty and chronic-heavy business model, as highlighted by management's optimism regarding the prescription business, which is benefiting from strong chronic therapy momentum. The integration of the BSV portfolio is expected to drive growth in both domestic and international markets, supporting Vista's forecast of stable revenue growth and margins. Despite short-term headwinds in the consumer healthcare segment, management anticipates a recovery, with a target of increasing the chronic therapy mix to 50%. This aligns with Vista's expectation of a 22% earnings CAGR over FY26-28, despite a slight reduction in FY27 earnings estimates. The Indian pharmaceutical sector's expanding landscape, characterized by improving pricing power and a strong pipeline of innovative products, further supports Mankind's growth trajectory. However, challenges such as geopolitical headwinds affecting international sales and the need for consistent execution remain critical watchpoints. Over the next 12-24 months, Mankind's focus on chronic therapies, successful product launches, and capacity expansion will be pivotal in navigating these challenges and capitalizing on growth opportunities
Why We Like This Stock
- Management's shift towards a higher-margin specialty and chronic-heavy business model is expected to enhance revenue and margins
- The integration of the BSV portfolio is anticipated to drive growth in both domestic and international markets
- A strong pipeline of innovative products and improving pricing power in the Indian pharmaceutical sector supports Mankind's growth outlook
Things To Watch Out For
- Short-term headwinds in the consumer healthcare segment may impact overall performance in the near term
- Geopolitical challenges are affecting international sales, posing risks to revenue growth
- The need for consistent execution and a stronger recovery in domestic Rx growth remains a critical concern
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 10,260 | 12,207 | 14,278 | 14,833 | 16,696 |
| Profit Before Tax (Cr.) | 2,264 | 2,194 | 2,463 | 2,816 | 3,302 |
| PBT Margin | 22.1% | 18.0% | 1725.0% | 19.0% | 19.8% |
| Net Profit (Cr.) | 1,801 | 1,670 | 1,847 | 2,110 | 2,441 |
| Earnings Per Share | 42.9 | 39.9 | 44.1 | 50.4 | 59.1 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Bernstein | ▼ Reduce | 2,057 | 22-May-2026 |
| Geojit Financials | ► Add | 2,660 | 16-Jun-2026 |
| HDFC Securities | ► Add | 2,850 | 03-Aug-2026 |
| JPMorgan | ► Neutral | 2,700 | 03-Aug-2026 |
| Jeffries | ▲ Buy | 3,000 | 08-Jul-2026 |
| Kotak Securities | ► Add | 2,680 | 21-May-2026 |
| Macguire | ▼ Underperform | 2,080 | 31-Jul-2026 |
| Morgan Stanley | ▲ Overweight | 2,735 | 21-May-2026 |
| Motilal Oswal | ▲ Buy | 2,975 | 31-Jul-2026 |
Company Overview
Show Company Profile
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.